US equities |
MU $877.55 ▲+2.46% NVDA $210.96 ▼-0.59% SPCX $147.49 ▲+1.89% AAPL $347.73 ▼-0.14% TSLA $372.22 ▼-0.63% SNDK $1,238.03 ▼-1.82% META $642.62 ▼-0.96% AMD $516.79 ▲+1.74%
FinancialContent

Articles published by BetterLife Pharma Inc.

News headline image
BetterLife Pharma Provides Scientific Update on Neuroplastogenic Activity of BETR-001
From BetterLife Pharma Inc.
Via GlobeNewswire
Tickers BETRF CSE:BETR
News headline image
BetterLife Provides Comments on CEO’s Share Position Ownership and Recent BCSC Press Release
From BetterLife Pharma Inc.
Via GlobeNewswire
Tickers BETRF CSE:BETR
News headline image
BetterLife Pharma Provides Scientific Update of Mechanism of Action of BETR-001 in Treatment of Psychiatric Disorders
From BetterLife Pharma Inc.
Via GlobeNewswire
Tickers BETRF CSE:BETR
News headline image
BetterLife Announces Debt Settlements
From BetterLife Pharma Inc.
Via GlobeNewswire
Tickers BETRF CSE:BETR
News headline image
BetterLife Pharma Appoints Corporate Advisor
From BetterLife Pharma Inc.
Via GlobeNewswire
Tickers BETRF CSE:BETR
News headline image
BetterLife Pharma Appoints New Director
From BetterLife Pharma Inc.
Via GlobeNewswire
Tickers BETRF CSE:BETR
News headline image
BetterLife Announces Debt Conversions
From BetterLife Pharma Inc.
Via GlobeNewswire
Tickers BETRF CSE:BETR
News headline image
USPTO Grants BetterLife’s BETR-001 Composition of Matter Patent
From BetterLife Pharma Inc.
Via GlobeNewswire
Tickers BETRF CSE:BETR
News headline image
BetterLife Announces Favorable Outcome in New York Legal Claims
From BetterLife Pharma Inc.
Via GlobeNewswire
Tickers BETRF CSE:BETR
News headline image
BetterLife Obtains Favourable Cardiac Safety Data for BETR-001
From BetterLife Pharma Inc.
Via GlobeNewswire
Tickers BETRF CSE:BETR
News headline image
BetterLife Obtains Favourable Genotoxicity Data for Oral BETR-001
From BetterLife Pharma Inc.
Via GlobeNewswire
Tickers BETRF CSE:BETR
News headline image
BetterLife Announces Fully Subscribed Private Placement Financing
From BetterLife Pharma Inc.
Via GlobeNewswire
Tickers BETRF CSE:BETR
News headline image
BetterLife Highlights Advantages of Non-hallucinogenic LSD Derivative BETR-001 and Publication of its Methods to Treat Mood Disorders Patent
From BetterLife Pharma Inc.
Via GlobeNewswire
Tickers BETRF CSE:BETR
News headline image
BetterLife Announces Closing of a Private Placement
From BetterLife Pharma Inc.
Via GlobeNewswire
Tickers BETRF CSE:BETR
News headline image
BetterLife To Present BETR-001 Preclinical Data at the 2024 Conference of the Federation of European Neuroscience Societies (FENS) in Vienna, Austria
From BetterLife Pharma Inc.
Via GlobeNewswire
Tickers BETRF CSE:BETR
News headline image
BetterLife Announces Closing of a Private Placement
From BetterLife Pharma Inc.
Via GlobeNewswire
Tickers BETRF CSE:BETR
News headline image
BetterLife Obtains Excellent Animal Cardiopulmonary Safety Data for Oral BETR-001
From BetterLife Pharma Inc.
Via GlobeNewswire
Tickers BETRF CSE:BETR
News headline image
BetterLife Announces Intent to Complete Private Placement of Units
From BetterLife Pharma Inc.
Via GlobeNewswire
Tickers BETRF CSE:BETR
News headline image
BetterLife Advances BETR-001 IND-enabling Studies
From BetterLife Pharma Inc.
Via GlobeNewswire
Tickers BETRF CSE:BETR
News headline image
BetterLife To Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference
From BetterLife Pharma Inc.
Via GlobeNewswire
Tickers BETRF CSE:BETR
News headline image
BetterLife Announces Closing of $1.168 Million Convertible Debentures to Further Advance IND-enabling Studies of its Non-hallucinogenic LSD-based Drug Candidate BETR-001
From BetterLife Pharma Inc.
Via GlobeNewswire
Tickers BETRF CSE:BETR
News headline image
BetterLife Announces Closing of Convertible Debentures For Further Development of BETR-001
From BetterLife Pharma Inc.
Via GlobeNewswire
Tickers BETRF CSE:BETR
News headline image
BetterLife’s 2-Bromo-LSD for Treatment of Depression Highlighted by Carleton University
From BetterLife Pharma Inc.
Via GlobeNewswire
Tickers BETRF CSE:BETR
News headline image
BetterLife Announces Closing of a Private Placement
From BetterLife Pharma Inc.
Via GlobeNewswire
Tickers BETRF CSE:BETR
News headline image
BetterLife Announces Extension of Warrants
From BetterLife Pharma Inc.
Via GlobeNewswire
Tickers BETRF CSE:BETR
News headline image
BetterLife Pharma to Host Investors Update Call on September 18, 2023
From BetterLife Pharma Inc.
Via GlobeNewswire
Tickers BETRF CSE:BETR
News headline image
US Patent and Trademark Office Publishes BetterLife’s Comprehensive Patent for BETR-001 and Other LSD Derivatives
From BetterLife Pharma Inc.
Via GlobeNewswire
Tickers BETRF CSE:BETR
News headline image
BetterLife Obtains Favourable Animal Safety Data for Repeated Oral Dosing of BETR-001
From BetterLife Pharma Inc.
Via GlobeNewswire
Tickers BETRF CSE:BETR
News headline image
BetterLife Highlights BETR-001 Article in Technology Networks Drug Discovery and Announces Closing of a Private Placement
From BetterLife Pharma Inc.
Via GlobeNewswire
Tickers BETRF CSE:BETR
News headline image
BetterLife Highlights American College of Physicians’ Updated Guidelines for Treating Depression and Announces Closing of Private Placement
From BetterLife Pharma Inc.
Via GlobeNewswire
Tickers BETRF CSE:BETR